期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Novel perspectives on combining immune checkpoint inhibitors and antiangiogenic drugs for advanced hepatocellular carcinoma
1
作者 linhui peng 《Oncology and Translational Medicine》 2025年第4期151-155,共5页
1.Introduction Liver cancer is the sixth leading cause of cancer and the third leading cause of cancer-related deaths globally(GLOBOCAN).Hepatocellular carcinoma(HCC)represents about 90%of primary liver cancers and co... 1.Introduction Liver cancer is the sixth leading cause of cancer and the third leading cause of cancer-related deaths globally(GLOBOCAN).Hepatocellular carcinoma(HCC)represents about 90%of primary liver cancers and constitutes a major global health problem.^([1])The number of new cases in China accounted for 46.6%of the global liver cancer cases,and 47.1%of the global liver cancer deaths occurred in China.^([2]) 展开更多
关键词 global liver cancer cases antiangiogenic drugs advanced hepatocellular carcinoma liver cancer global health problem liver cancers immune checkpoint inhibitors primary liver cancers
暂未订购
上一页 1 下一页 到第
使用帮助 返回顶部